From: First experience with MR-guided focused ultrasound in the treatment of Parkinson's disease
Patient no. | Pre-FUS l-dopa equivalents (mg/day) | 3 months post-FUS l-dopa equivalents (mg/day) | Pre-FUS dopamine agonists (mg/day) | 3 months post-FUS dopamine agonists (mg/day) | |
---|---|---|---|---|---|
Group 1 | 1 | 1,000 | 1,000 | Ropinirol: 3 | Ropinirol: 3 |
Amantadine: 300 | Amantadine: 300 | ||||
Biperiden: 4 | Biperiden: 4 | ||||
2 | 800 | 800 | - | - | |
3 | 300 | - | - | - | |
4 | 600 | 600 | Biperiden: 6 | - | |
Group 2 | 5 | 1,000 | - | - | - |
6 | 1,000 | - | - | - | |
7 | 1,200 | 600 | Ropinirol: 2 | Ropinirol: 2 | |
8 | - | - | - | - | |
9 | 600 | 1,000 | Rotigotine: 8 | - | |
10 | 1,000 | 600 | Ropinirol: 10 | - | |
11 | - | - | Amantadine: 1,000 | Amantadine: 600 | |
12 | 800 | 800 | Ropinirol: 4 | Ropinirol: 4 | |
13 | 800 | 500 | Amantadine: 300 | Amantadine: 300 | |
Entacapone: 1,600 | Entacapone: 1,000 | ||||
Mean | 827 | 536 |